BGI

Shenzhen, China Founded: 1999 • Age: 27 yrs Listed
BGI is engaged in genomics and precision medicine solutions.

About BGI

BGI is a publicly listed company based in Shenzhen (China) founded in 1999. BGI is engaged in genomics and precision medicine solutions. It operates on a HealthTech and Professional Services model. The company has 3,700 employees. Its chief executive, as recorded, is Wang Jian. Its website bgi.com draws about 152 thousand monthly visits. BGI offers products and services including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis. Its focus areas include Biotechnology and Genomics. Its legal entity is Shenzhen BGI Genomics Co., Ltd. Its competitors include Novogene Corporation and Beikang Medical; 2 of its 2 listed competitors have raised funding.

Company details

BGI, based in Shenzhen, China, is focused on advancing life sciences through genomics and precision medicine. The company is involved in genetic testing, oncology solutions, and rare disease diagnosis. Services are provided across maternal and child health, tumor prevention, infectious disease control, and chronic disease management. Operations span multiple regions in China, integrating clinical, research, and public health initiatives to enhance healthcare outcomes. BGI is committed to reducing birth defects and improving global health standards through innovative technologies.

  • Headquarters Shenzhen, China
  • Employees 3,700
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website bgi.com
  • Social LinkedIn X Facebook
  • Legal Name Bgi Genomics Co. Ltd. Class A
Key Metrics
  • Annual Revenue
    $528.49 M (USD)
    -4.21
    as on Dec 31, 2025
  • Net Profit
    -$88.08 M (USD)
    31.69
    as on Dec 31, 2025
  • EBITDA
    $734.18 K (USD)
    as on Dec 31, 2025
  • Latest Funding Round
    $300M (USD), Post-IPO

    Feb 2021

  • Investors
    SDIC

    & 1 more

  • Employee Count
    3,700

Products & Services of BGI

BGI offers a comprehensive portfolio of products and services, including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis.

NIFTY®200+
Genetic Testing

Non-invasive prenatal testing for single-gene disorders offered.

Liver and Pancreatic Tumor Testing
Oncology

Genetic testing for late-stage tumor survival solutions.

Rare Disease Genomic Diagnosis
Genomics

Genomic solutions for rare disease diagnosis provided.

Funding Insights of BGI

  • Total Rounds 2
  • Last Round Post-IPO — $300M
  • First Round $350,669

    (Jan 2015)

  • Investors Count 2

All 2 funding rounds of BGI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2021$300MPost-IPO––
Jan 2015$350,669Grant––
Valuation history

2 investors in total: 2 institutional.

Investors in BGI

BGI has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SDIC and European Union.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Investment holding company
1995sdic.com.cnBeijing, China
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Premium access

Investor details for BGI

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of BGI

50 people are tracked at BGI (8 in leadership, 14 in board & advisors, 28 in team); the tracked headcount is 3,700.

NameRoleGroup
Wang Jian
Chairman & CEOLeadership
Yin Ye
General ManagerLeadership
Ray Wong
Domestic BD Director For Medicalbigdata Reasearch At BGI GroupLeadership
Mark Sun
HR DirectorLeadership
Hongyan An
Director Of Sale/business Unit HeadLeadership
Hang Su
HR Business PartnerLeadership
Chao Jia
Internet Product DirectorLeadership
Jessica Wang
Chief Product DirectorLeadership
Wu Chun
Board MemberBoard & advisors
Li Songgang
Supervisory Board ChairmanBoard & advisors
Chen Penghui
Board MemberBoard & advisors
Xu Aimin
Independent Board MemberBoard & advisors
Guo Jinlong
Independent Board MemberBoard & advisors
Jiang Changjian
Independent Board MemberBoard & advisors
Li Yingrui
Board MemberBoard & advisors
Zhao Qian
Board MemberBoard & advisors
Wang Hongtao
Board MemberBoard & advisors
Sun Yingjun
Board MemberBoard & advisors
Xie Hong
Independent Board MemberBoard & advisors
Jin Chunbao
Board MemberBoard & advisors

30 more people are available in the full profile.

Premium access

Complete people profiles for BGI

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of BGI

BGI is a publicly listed company on the SZSE with ticker symbol 300676 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Jul 2017
  • Listed onSZSE: 300676
  • Listed entityBGI Genomics Co. Ltd. Class A
  • Exchange sectorHealth technology
  • ISINCNE100003449
  • Share price42.34 CNY (-1.42% on the day) · 2026-10-14
  • Market capitalisation17,794,916,179.00 CNY
  • EPS (diluted, trailing year)-1.38 CNY
  • Volume (last session)7,502,042

Financials of BGI

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
20253.70B CNY-616.7M CNY5.1M CNY
20243.86B CNY-902.7M CNY-132.1M CNY
20234.34B CNY92.9M CNY582.6M CNY
20227.05B CNY802.8M CNY1.22B CNY
20216.75B CNY1.46B CNY2.02B CNY
Premium access

Detailed financial statements for BGI

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of BGI

4 dated milestones of BGI across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded BGI is founded.
  2. Funding First funding round of $351K.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $300.0M.

Competitors of BGI

BGI has 2 listed competitors in our database, 2 of them funded. They include Novogene Corporation and Beikang Medical.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
novogene.com2011Beijing, China$75M141
Genomic services and solutions with NGS expertise are provided.
basecare.cn2010Suzhou, China$36.52M
NGS-based diagnostic solutions for neonatal screening are developed.
Premium access

Detailed competitors of BGI

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of BGI

The website of BGI (bgi.com) receives about 152.2K visits a month.

  • Monthly visits
    152.2K

    ▲ 52.9% vs previous month

Similar websites

Websites whose visitors overlap most with BGI. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
genomics.cn
100%
257.6K#132,136View details
cd-genomics.com
cd-genomics.com
80%
#300,823–
cloud.majorbio.com
cloud.majorbio.com
78%
–
yeasen.com
71%
69K#449,589View details
rna-seqblog.com
71%
#669,184View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 15 similar websites and full traffic analytics for BGI

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 15 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bgi

Premium access

Complete news archive for BGI

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about BGI

BGI was founded in 1999 and raised its 1st funding round 16 years after it was founded.

BGI is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.

Wang Jian is the CEO of BGI, as recorded in our data.

BGI has 3,700 employees.

Annual revenue of BGI is $528.49M as on Dec 31, 2025.

BGI, based in Shenzhen, China, is focused on advancing life sciences through genomics and precision medicine. The company is involved in genetic testing, oncology solutions, and rare disease diagnosis. Services are provided across maternal and child health, tumor prevention, infectious disease control, and chronic disease management. Operations span multiple regions in China, integrating clinical, research, and public health initiatives to enhance healthcare outcomes. BGI is committed to reducing birth defects and improving global health standards through innovative technologies.

BGI's top competitors include Novogene Corporation and Beikang Medical.

BGI offers NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis.

Yes, BGI is publicly traded on SZSE under the ticker symbol 300676.

BGI has 2 investors. Key investors include SDIC, and European Union.

BGI operates through Shenzhen Bgi Genomics Co., Ltd..

The website of BGI receives about 152 thousand visits a month.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available